The Medical Letter on Drugs and Therapeutics
Arformoterol (Brovana) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Arformoterol (Brovana) for COPD
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Arformoterol (Brovana) for COPD
Article code: 1264a
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.